Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adocia is Extending its Intellectual Property to New Formulations of Monoclonal Antibodies

Published: Tuesday, October 23, 2012
Last Updated: Tuesday, October 23, 2012
Bookmark and Share
These patents cover innovative formulations of monoclonal antibodies enabling a subcutaneous injection, in order to improve patients’ lives and reduce treatment costs.

Adocia has announced that it has filed another three patent applications covering new formulations of monoclonal antibodies.

More specifically, these patent applications relate to original formulations that facilitate the subcutaneous administration of antibodies, as well as innovative formulations that reduce antibody aggregation.

Monoclonal antibodies are therapeutic proteins that are effective in treating numerous chronic diseases: cancer, osteoporosis, multiple sclerosis and other inflammatory diseases. At present, these proteins are mostly administered intravenously.

Subcutaneous administration is now the preferred method as it makes patients’ lives easier and reduces the costs of treatment.

This mode of administration, however, requires a highly-concentrated formulation of monoclonal antibodies. These have a high viscosity and create problems when it comes to administration with subcutaneous injection systems.

Two of the patent applications filed by Adocia relate to innovative formulations that efficiently reduce the viscosity of concentrated antibody solutions.

In a third application, Adocia is seeking patent protection for a new, simple and effective means of reducing antibody aggregation in both concentrated and diluted solutions.

The regulatory authorities in the United States (FDA) and Europe (EMA) are more demanding, since these aggregates can be immunogenic and can result in the treatment being halted.

“We have clearly identified the specific problems that these proteins pose for the pharmaceutical industry,” said Olivier Soula, Adocia’s research director. “We think our innovative formulations provide effective, low-cost solutions to these problems. We are currently presenting the new formulations to a large number of pharmaceutical companies, who are showing considerable interest in them.”

Adocia is already involved in two collaborations with biopharmaceutical companies and intends to enter into more.

“Adocia is continuing to innovate in major pharmaceutical industry applications,” said the company’s president and CEO, Gerard Soula. “The monoclonal antibody market represents a major opportunity for us, since it was worth USD 45 billion in 2011 and is expected to reach USD 58 billion in 2016.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Iron Regulators Join War on Pathogens
Iron regulatory proteins (IRPs) play an important role in the body’s immune system.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!